Arbutus Biopharma (ABUS) has provided an update.
Arbutus Biopharma Corporation, Genevant Sciences, and Moderna, Inc. have agreed to seek a delay in their ongoing patent infringement lawsuit concerning Moderna’s COVID-19 vaccine, MRNA-1273. The request for an extension aims to allow additional time for discovery, potentially postponing the trial start to late September 2025, pending court approval. This legal development could influence the stock performance of the companies involved.
Learn more about ABUS stock on TipRanks’ Stock Analysis page.
